Skip to main content
Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) is embarking on a new clinical trial for individuals with Post-Treatment Lyme Disease Syndrome (PTLDS). PTLDS is a condition in which the symptoms of Lyme Disease remain for more than 6 months after treatment. This is exciting news for millions of sufferers.

The Post-Treatment Lyme Disease Syndrome Study

The Johns Hopkins study will test whether psilocybin is safe and helpful for improving fatigue, pain, mood, and quality of life in people with PTLDS.  It will be led by Dr. Albert Garcia-Romeu of the CPCR, in collaboration with Drs. John Aucott and Mark Soloski at the Johns Hopkins Lyme Disease Research Center.

Why is this so important?

According to the CDC, “Lyme Disease is caused by infection with the bacterium Borrelia burgdorferi. Although most cases of Lyme disease can be cured with a 2- to 4-week course of oral antibiotics, patients can sometimes have symptoms of pain, fatigue, or difficulty thinking that last for more than 6 months after they finish treatment. This condition is called Post-Treatment Lyme Disease Syndrome (PTLDS).”

“It is not known why some patients experience PTLDS.  Some experts believe that Borrelia burgdorferi can trigger an “auto-immune” response causing symptoms that last well after the infection itself is gone.” – CDC 

No proven treatment to date for PTLDS

The CDC reports,  that unfortunately there is no proven treatment for PTLDS.

“Although short-term antibiotic treatment is a proven treatment for early Lyme Disease,  funded by the National Institutes of Health (NIH) it has found that long-term outcomes are no better for patients who receive additional prolonged antibiotic treatment than for patients who receive a placebo. Long-term antibiotic treatment for Lyme disease has been associated with serious, sometimes deadly complications, as described in the links below.”

PTLDS can have an extremely negative impact on a person’s life.  Indeed,  living with PTLDS was brought back into the limelight recently by a Netflix documentary on country and western star  Shania Twain.  In an interview with USA Today, she relived her experience after being bitten by a tick. Shania lost her voice along with intense fatigue and other symptoms. The mega star was unable to perform for some time. This impacted her personal and professional life significantly.

Shania Twain lyme disease [longevity live]

Other Advances in Psychedelic Science

Johns Hopkins is considered the leading researcher into the health benefits of psychedelics  (of which psilocybin is just one) in the United States.

It started back in 2000 when a research group from Johns Hopkins were the first scientists in the US to get regulatory approval to research  psychedelics in healthy, psychedelic-naive volunteers.

Using psilocybin under medical supervision

Psychedelics are categorized as Schedule 1 of the Controlled Substances Act in the US. This classification is reserved for drugs with high abuse potential; no accepted medical use; and lack of safety even under medical supervision. 

Groundbreaking Johns Hopkins studies

A 2006 publication by Johns Hopkins on the safety and enduring positive effects of a single dose of psilocybin is widely considered a landmark study that sparked a renewal of psychedelic research worldwide.

Since then, they have published further groundbreaking studies in more than 60 peer-reviewed articles in respected scientific journals.

This makes Johns Hopkins the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.

psilocybin therapy at Johns Hopkins

Candidates for trials

In partnership with Columbia University, CPCR researchers recently launched a new survey study on how psychedelic experiences can impact romantic relationships. Couples are eligible to participate if (1) both members of the couple have used a psychedelic together or (2) only one member of the couple used a psychedelic during the time they were in their romantic relationship.

mm

Gisèle Wertheim Aymes

Gisèle is the owner of the Longevity brand and a self-proclaimed health hedonist. When she is not working, you'll find in her in a yoga class or active in the great outdoors. Gisèle is passionate about health and sharing information. You can follow her @giselewaymes on Twitter and Instagram or read her Linked-In profile for full bio details.

The content in this editorial is for general information only and is not intended to provide medical or other professional advice. For more information on your medical condition and treatment options, speak to your healthcare professional.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.